Participation of members from Oslo Diabetes Research Centre at EASD 2017

Several abstracts by  members from  Oslo Diabetes Research Centre have been accepted for presentation at the annual EASD in Lisboa September 11-15, 2017:

1. Time-trends in incidence and prevalence of type 2 diabetes patients requiring glucose-lowering treatment from 2007-2015: nationwide data from Norway and Sweden. D. Nathanson, J. Bodegard, A. Norhammar, K.I. Birkeland, T. Nyström, M. Thuresson, J.W. Eriksson, H.L. Gulseth

2. Type 2 diabetes in general practice in Norway, status and time trends. Å. Bakke, J.G. Cooper, G. Thue, I. Dalen, S. Skeie, S. Carlsen, E.R. Oord, K.F. Løvaas, T.V. Madsen, A.T. Tran, A.K. Jenum, T.J. Berg, B. Gjelsvik, T. Claudi, S. Sandberg

3. Plasma soluble leptin receptor predicts insulin sensitivity in humans. C. Sommer, S. Lee, H.L. Gulseth, J. Jensen, C.A. Drevon, K.I. Birkeland

4. Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVD-REAL study. M.A. Cavender, A. Norhammar, K.I. Birkeland, M.E. Jørgensen, J.P. Wilding, K. Khunti, A.Z. Fu, J. Bodegård, B. Blak, E.T. Wittbrodt, M. Thuresson, P. Fenici, N. Hammar, M. Kosiborod, on behalf of the CVDREAL Investigators and StudyGroup

5. Total events of hospitalisation for heart failure in new users of SGLT-2 inhibitors: real world data from 5 countries and more than 298,000 patients: the CVD-REAL study. M. Kosiborod, M.A. Cavender, A.Z. Fu, A. Norhammar, K.I. Birkeland, M. Jørgensen, R.W. Holl, N. Hammar, E.T. Wittbrodt, J. Bodegård, M. Scheerer, M. Thuresson, P. Fenici, on behalf of the CVD-REAL Investigators and StudyGroup

6. Dapagliflozin is associated with lower risk of major adverse cardiovascular events compared to DPP-4i in type 2 diabetes patients. Results from CVD-REAL Nordic. A. Norhammar, M. Kosiborod, H. Gulseth, J.W. Eriksson, P. Fenici, D. Nathanson, J. Bodegard, M. Thuresson, T. Nyström, K.I. Birkeland

7. Dapagliflozin compared to DPP4i treatment is associated with lower risk of kidney disease, heart failure and all-cause death: CVD-REAL Nordic. J.W. Eriksson, A. Norhammar, J. Bodegard, M. Thuresson, P. Fenici, D. Nathanson, M. Kosiborod, H.L. Gulseth, T. Nyström, K.I. Birkeland

8. Second line treatment after metformin monotherapy of type 2 diabetes in a real life setting 2006 to 2015: nationwide data comparison between Denmark, Norway and Sweden. F. Persson, J. Bodegard, T. Nyström, D. Nathanson, M. Thuresson, M. Linnemann Jensen, M.E. Jørgensen, K.I. Birkeland, H.L. Gulseth, A. Norhammar, J.W. Eriksson

9. Life years lost and cardiovascular risk in type 2 diabetes patients requiring glucoselowering treatment 2008-2015: nationwide data from Norway and Sweden. H.L. Gulseth, J. Bodegard, A. Norhammar, D. Nathanson, M. Thuresson, K.I. Birkeland, J.W. Eriksson, T. Nyström

10. Indexes of body fat, but not BMI, are associated with cardiovascular (CV) mortality in subjects with diabetes (DM) during 17 year follow-up in the Norwegian HUNT2 study. A.P. Ofstad, C. Sommer, K.I. Birkeland, M.R. Bjørgaas, J.M. Gran, O.E. Johansen, H.L. Gulseth

11. Enteroviruses in the pancreas of live adult patients with newly diagnosed type 1 diabetes. Results from the DiViD study. L. Krogvold, A. Genoni, A. Puggioni, D. Campani, S. Richardson, B. Edwin, T. Buanes, K. Dahl-Jørgensen, A. Toniolo

12. Pandemic influenza diagnosis and subsequent risk of type 1 diabetes. P.L.D. Ruiz, G. Tapia, I.J. Bakken, S.E. Håberg, H.L. Gulseth, L.C. Stene